share_log

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23

Benzinga ·  Nov 14 22:16  · Ratings

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $15 to $23.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment